Spruce Biosciences, Inc. Fair Value Adjustment of Warrants
Spruce Biosciences, Inc. (SPRB) reported Fair Value Adjustment of Warrants of -$524.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:FairValueAdjustmentOfWarrants · last filed 2026-08-12
- Spruce Biosciences, Inc. fair value adjustment of warrants for the quarter ending 2026-06-30 was -$615.00K.
- Spruce Biosciences, Inc. fair value adjustment of warrants for the quarter ending 2026-03-31 was $91.00K.
- Spruce Biosciences, Inc. fair value adjustment of warrants for the quarter ending 2025-12-31 was $4.02M.
- Spruce Biosciences, Inc. fair value adjustment of warrants for the quarter ending 2025-09-30 was $102.00K.
- Spruce Biosciences, Inc. fair value adjustment of warrants for fiscal 2025 was $3.50M.
- Spruce Biosciences, Inc. fair value adjustment of warrants for fiscal 2024 was $0.00.
| Period end | Fair Value Adjustment of Warrants 3 month | Fair Value Adjustment of Warrants 6 month | Fair Value Adjustment of Warrants 9 month | Fair Value Adjustment of Warrants 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$615.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | -$524.00K 10-Q · filed 2026-08-12 | $3.49M derived: sum of 3 quarters · filed 2026-08-12 | $3.60M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | $91.00K 10-Q · filed 2026-05-13 | $4.11M derived: sum of 2 quarters · filed 2026-05-13 | $4.21M derived: sum of 3 quarters · filed 2026-05-13 | $3.75M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | $4.02M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $4.12M derived: sum of 2 quarters · filed 2026-03-09 | $3.66M derived: sum of 3 quarters · filed 2026-08-12 | $3.50M 10-K · filed 2026-03-09 |
| 2025-09-30 | $102.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | -$359.00K derived: sum of 2 quarters · filed 2026-08-12 | -$517.00K 10-Q · filed 2025-11-10 | -$517.00K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | -$461.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | -$619.00K 10-Q · filed 2026-08-12 | -$619.00K derived: sum of 3 quarters · filed 2026-08-12 | -$619.00K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | -$158.00K 10-Q · filed 2026-05-13 | -$158.00K derived: sum of 2 quarters · filed 2026-05-13 | -$158.00K derived: sum of 3 quarters · filed 2026-05-13 | -$158.00K derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $0.00 derived: sum of 2 quarters · filed 2026-03-09 | $0.00 derived: sum of 3 quarters · filed 2026-03-09 | $0.00 10-K · filed 2026-03-09 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $0.00 derived: sum of 2 quarters · filed 2025-11-10 | $0.00 10-Q · filed 2025-11-10 | |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $0.00 10-Q · filed 2025-08-14 | ||
| 2024-03-31 | $0.00 10-Q · filed 2025-05-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |